ZURICHâ€”Novartis AG is distancing itself from the era of Daniel Vasella, the former chairman whose controversial exit package blemished the Swiss pharmaceutical company's image when he stepped down a year ago. . In November, Novartis struck a $1.68 billion deal to sell the bulk of its diagnostics business to a Spanish company, the first indication it would slim down the sprawling portfolio of businesses Dr. Vasella had assembled over two decades. A month later, Novartis said it was scrapping plans to build a training center...
  